Clinical Trial Update: GRK4 Polymorphisms Blood Pressure Response to Candesartan [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update investigating whether GRK4 polymorphisms influence blood pressure response to candesartan in patients with essential hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension

Drugs mentioned

• Candesartan (candesartan)

Snippet

Sponsor: Third Military Medical University | Conditions: Essential Hypertension | Phase 4 | Status: UNKNOWN